Does the media prefer DYN or RDY?

In the previous week, Dyne Therapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Dyne Therapeutics and 1 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 1.01 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DYN or ARWR?

In the previous week, Dyne Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Dyne Therapeutics and 11 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.08 beat Dyne Therapeutics' score of 1.01 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 5 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or DYN?

In the previous week, Dyne Therapeutics had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 12 mentions for Dyne Therapeutics and 10 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.15 beat Dyne Therapeutics' score of 1.01 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRAX or DYN more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer PRAX or DYN?

In the previous week, Dyne Therapeutics had 9 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Dyne Therapeutics and 3 mentions for Praxis Precision Medicines. Dyne Therapeutics' average media sentiment score of 1.01 beat Praxis Precision Medicines' score of 0.62 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DYN or CYTK?

In the previous week, Dyne Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Dyne Therapeutics and 11 mentions for Cytokinetics. Dyne Therapeutics' average media sentiment score of 1.01 beat Cytokinetics' score of 1.00 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dyne Therapeutics (DYN) Competitors

$19.33 +0.77 (+4.15%)

Closing price 04:00 PM Eastern

Extended Trading

$19.33 0.00 (0.00%)

As of 07:09 PM Eastern

Compare

DYN vs. RDY, ARWR, ELAN, PRAX, and CYTK

Should you buy Dyne Therapeutics stock or one of its competitors? MarketBeat compares Dyne Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyne Therapeutics include Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Elanco Animal Health (ELAN), Praxis Precision Medicines (PRAX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Dyne Therapeutics (NASDAQ:DYN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Dyne Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

In the previous week, Dyne Therapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Dyne Therapeutics and 1 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 1.01 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Dr. Reddy's Laboratories	$3.58B	3.18	$484.20M	$0.58	23.53

Dyne Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 81.07%. Dr. Reddy's Laboratories has a consensus price target of $16.90, suggesting a potential upside of 23.85%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Dyne Therapeutics (NASDAQ:DYN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

In the previous week, Dyne Therapeutics had 1 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Dyne Therapeutics and 11 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.08 beat Dyne Therapeutics' score of 1.01 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	5 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 81.07%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, indicating a potential upside of 12.69%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Arrowhead Pharmaceuticals	$829.45M	13.23	-$1.63M	-$2.15	N/A

Dyne Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Dyne Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Elanco Animal Health has higher revenue and earnings than Dyne Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.53	-$232M	-$0.50	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Elanco Animal Health currently has a consensus price target of $28.20, indicating a potential upside of 18.19%. Dyne Therapeutics has a consensus price target of $35.00, indicating a potential upside of 81.07%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 12 mentions for Dyne Therapeutics and 10 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.15 beat Dyne Therapeutics' score of 1.01 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Praxis Precision Medicines has higher revenue and earnings than Dyne Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,141.19	-$303.27M	-$13.37	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Praxis Precision Medicines' return on equity of -43.02% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 9 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Dyne Therapeutics and 3 mentions for Praxis Precision Medicines. Dyne Therapeutics' average media sentiment score of 1.01 beat Praxis Precision Medicines' score of 0.62 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines presently has a consensus target price of $592.67, indicating a potential upside of 69.35%. Dyne Therapeutics has a consensus target price of $35.00, indicating a potential upside of 81.07%. Given Dyne Therapeutics' higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Summary

Praxis Precision Medicines beats Dyne Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Cytokinetics?

Dyne Therapeutics (NASDAQ:DYN) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Dyne Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 81.07%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 29.36%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dyne Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Dyne Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Dyne Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Dyne Therapeutics and 11 mentions for Cytokinetics. Dyne Therapeutics' average media sentiment score of 1.01 beat Cytokinetics' score of 1.00 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dyne Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Cytokinetics	$88.04M	108.49	-$784.96M	-$6.84	N/A

Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

Dyne Therapeutics beats Cytokinetics on 13 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.07B	$3.03B	$6.49B	$12.59B
Dividend Yield	N/A	1.97%	2.69%	5.23%
P/E Ratio	-6.00	17.54	21.44	26.23
Price / Sales	N/A	348.86	562.78	112.66
Price / Cash	N/A	56.66	43.65	57.38
Price / Book	3.70	6.31	10.60	7.33
Net Income	-$446.21M	$75.84M	$3.56B	$337.06M
7 Day Performance	11.28%	3.33%	2.97%	3.43%
1 Month Performance	11.03%	2.06%	6.25%	7.24%
1 Year Performance	57.92%	32.76%	36.72%	37.97%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.5199 of 5 stars	$19.33 +4.1%	$35.00 +81.1%	+57.8%	$3.07B	N/A	N/A	100	Positive News
RDY Dr. Reddy's Laboratories	2.8169 of 5 stars	$13.62 +0.0%	$16.90 +24.1%	-7.2%	$11.36B	$3.58B	23.47	27,811
ARWR Arrowhead Pharmaceuticals	2.6474 of 5 stars	$73.95 -3.5%	$87.80 +18.7%	+408.0%	$10.80B	$829.45M	N/A	400	Positive News
ELAN Elanco Animal Health	4.1092 of 5 stars	$19.97 +0.6%	$28.20 +41.2%	+78.8%	$9.92B	$4.72B	N/A	9,400
PRAX Praxis Precision Medicines	3.1272 of 5 stars	$320.53 -6.4%	$592.67 +84.9%	+852.3%	$9.55B	$8.55M	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ARWR, ELAN, PRAX, and CYTK

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Summary

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Summary

How does Dyne Therapeutics compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ARWR, ELAN, PRAX, and CYTK

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Is DYN or RDY more profitable?

Does the media prefer DYN or RDY?

Which has preferable valuation & earnings, DYN or RDY?

Do analysts prefer DYN or RDY?

Which has more volatility and risk, DYN or RDY?

Do insiders & institutionals hold more shares of DYN or RDY?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media favor DYN or ARWR?

Which has more risk & volatility, DYN or ARWR?

Do institutionals and insiders believe in DYN or ARWR?

Do analysts prefer DYN or ARWR?

Which has higher valuation and earnings, DYN or ARWR?

Is DYN or ARWR more profitable?

Summary

How does Dyne Therapeutics compare to Elanco Animal Health?

Which has higher earnings and valuation, ELAN or DYN?

Do analysts rate ELAN or DYN?

Which has more risk & volatility, ELAN or DYN?

Do institutionals & insiders hold more shares of ELAN or DYN?

Is ELAN or DYN more profitable?

Does the media favor ELAN or DYN?

Summary

How does Dyne Therapeutics compare to Praxis Precision Medicines?

Which has more volatility and risk, PRAX or DYN?

Which has higher earnings and valuation, PRAX or DYN?

Is PRAX or DYN more profitable?

Does the media prefer PRAX or DYN?

Do insiders & institutionals have more ownership in PRAX or DYN?

Do analysts prefer PRAX or DYN?

Summary

How does Dyne Therapeutics compare to Cytokinetics?

Do analysts recommend DYN or CYTK?

Is DYN or CYTK more profitable?

Does the media favor DYN or CYTK?

Do insiders and institutionals believe in DYN or CYTK?

Which has stronger earnings & valuation, DYN or CYTK?

Which has more risk and volatility, DYN or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools